CAMBRIDGE, MA — (Marketwire) — 02/08/13 — (“Radius”), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women-s health conditions, announced today that it will present at the 15th annual BIO CEO & Investor Conference in New York, NY. Michael Wyzga, President and CEO of Radius Health, is scheduled to present on Monday, Feb. 11, at 2:15 p.m. (EST).
Radius will provide an update on the company and its Phase 3 asset, BA058, a novel anabolic, bone-building compound under development as a potential treatment for postmenopausal women with osteoporosis at high risk for fracture. BA058-SC, an injectable form of BA058, is currently in a Phase 3 trial, and BA058-TD, is in a Phase 2 trial studying the efficacy of delivering BA058 via transdermal patch. Radius and 3M Drug Delivery Systems have an exclusive partnership agreement for development and commercialization of BA058-TD.
BIO CEO & Investor
Monday, Feb. 11
2:15 p.m. EST
Waldorf Astoria, NY (Park South)
301 Park Ave.
New York, NY 10022
The Radius presentation will be available one hour after the presentation via a webcast here:
Radius is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women-s health conditions. Radius is committed to the development of advanced therapeutics for the large and underserved osteoporosis market. The Company-s lead product candidate, BA058-SC, is in development to reduce the risk of complications associated with osteoporosis, such as fracture. The company also has a next-generation transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. Learn more by visiting the company-s new website at
Dave Connolly
617-374-8800
Lisa DeScenza
617-374-8800